Symprove acquired by US-based Metagenics following rapid growth

UK-based gut health brand Symprove has today announced it is joining the US-based Metagenics group, marking a significant new chapter in the company’s growth journey.

The acquisition sees Symprove become part of Metagenics, a California-based nutritional supplement distributor. The move follows Symprove’s partnership with BD-Capital in 2020, during which time the business has more than tripled in size.

In a statement shared on LinkedIn, Symprove said: "Finding the right next partner was critical - one that shares Symprove’s deep commitment to science, healthcare practitioner advocacy and real patient impact.

"In Metagenics we have found exactly that partner, and this marks an exciting new chapter: taking Symprove’s life-changing, patented formulation to a truly global consumer and patient audience."

The partnership is intended to support Symprove’s international expansion, with the brand aiming to bring its patented, liquid gut health formulation to a significantly broader global consumer and patient audience.

Symprove confirmed that its leadership structure will remain unchanged. Chief Executive Officer Will Bowler and the existing management team will continue to lead the business from its headquarters in Surrey, UK. Founder Barry Smith, who established Symprove 40 years ago, will also remain involved with the brand as a key ambassador.

While financial terms of the deal were not disclosed, the move positions Symprove within a global nutrition platform as demand continues to grow for clinically supported gut health solutions.